Lazaro Garcia

TL;DR: A test based on massively parallel DNA sequencing to characterize base substitutions, short insertions and deletions (indels), copy number alterations and selected fusions across 287 cancer-related genes from routine formalin-fixed and paraffin-embedded (FFPE) clinical specimens is described.

TL;DR: Applying a next-generation sequencing assay targeting 145 cancer-relevant genes in 40 colorectal cancer and 24 non–small cell lung cancer formalin-fixed paraffin-embedded tissue specimens identified at least one clinically relevant genomic alteration in 59% of the samples and revealed two gene fusions, C2orf44-ALK in a colorective cancer sample and KIF5B-RET in a lung adenocarcinoma.

TL;DR: A novel next-generation sequencing-based assay to identify all classes of genomic alterations using archived formalin-fixed paraffin-embedded blood and bone marrow samples with high accuracy in a clinically relevant time frame is developed, which increases the ability to identify clinically relevant genomic alterations with therapeutic relevance.

TL;DR: Comprehensive genomic profiling of ACC can identify actionable GAs in a subset of patients that could influence therapy for these difficult-to-treat progressive neoplasms.

TL;DR: This poster presents a poster presented at the 2016 European Society for Medical Oncology Congress on Wednesday, 3 March 2016 entitled “Advances in Immunotherapy for Pediatric Oncological Tumors: Promoting Consistency in Patients with Previously Undiagnosed Tumor Associated with Alcohol Dependence.”